LAP2 Isoform Profile in Heart Ageing and in Cardiac Cell Proliferation and Differentiation: Input From CRISPR-Cas9-mediated LAP2a Knockdown in H9C2.

Nathalie Vadrot, Maryline Moulin, Ana Ferreiro, Pascale Richard, Brigitte Buendia

Abstract read

In one paragraph

Article in International journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Elucidating Gene Functions in Congenital Heart Disease.Current treatment options in cardiovascular medicine · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nathalie VadrotBasic and Translational Myology laboratory, Université Paris Cité, CNRS, BFA, 75013 Paris, France.

Maryline MoulinBasic and Translational Myology laboratory, Université Paris Cité, CNRS, BFA, 75013 Paris, France.

Ana FerreiroBasic and Translational Myology laboratory, Université Paris Cité, CNRS, BFA, 75013 Paris, France.

Pascale RichardAPHP- Sorbonne Université, Unité Fonctionnelle de Cardiogénétique et Myogénétique Moléculaire, Service de Biochimie Métabolique, HU Pitié Salpêtrière- Charles Foix, Paris, France.

Brigitte BuendiaBasic and Translational Myology laboratory, Université Paris Cité, CNRS, BFA, 75013 Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Haploinsufficiency of Lap2 alpha (LAP2a), a nuclear partner of Lamins A/C, has been associated with cardiac disease in rare cases, but LAP2a function remains largely unknown. To investigate the functional role of LAP2a in cardiomyocytes, we generated clones of embryonic myocardium-derived H9C2 cells in which LAP2a expression was specifically reduced through gene editing of the LAP2a gene

Indexed as

AgingDNA-Binding ProteinsMembrane ProteinsMyocytes, CardiacAnimalsCell DifferentiationCell LineCell ProliferationCRISPR-Cas SystemsGene Knockdown TechniquesHumansMEF2 Transcription FactorsMiceMyocardiumProtein IsoformsRatsDNA-Binding Proteinslamina-associated polypeptide 2MEF2 Transcription FactorsMembrane ProteinsProtein Isoformsageing.cardiomyopathycell differentiationcell proliferationH9C2heartLAP2

Identifiers

PMID41799755

DOI10.7150/ijms.114095

PMCPMC12964562

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.